EML4 and non-small cell lung carcinoma: Therefore, we decided to investigate the activity of all clinically relevant second-generation ALK inhibitors on a panel of 6 mutated forms of ALK, associated with crizotinib resistance in EML4-ALK-positive NSCLC patients, in an NPM-ALK-positive model.